Krystal Biotech to Present at Upcoming Investor Conferences
Krystal Biotech, Inc. 2026 Q3 - Results - Earnings Call Presentation
Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412
TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380
RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375
Krystal Biotech (KRYS) Stock Stays Above Fair Value After Buyback Plan
Earnings Beat May Change The Case For Krystal Biotech (KRYS) Stock
Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?
Krystal Biotech Sinks 11% Despite Q3 Beat as Eye Trial Enrollment “Progressed Slower Than Initially Anticipated”
Krystal Biotech Inc (KRYS) (Q3 2026) Earnings Call Highlights: Vyjuvek Revenue Jumps 30% to ...
Krystal Biotech, Inc. Q3 2026 Earnings Call Summary
Krystal Biotech (KRYS) Q3 2026 Earnings Call Transcript
Krystal Biotech Q3 Earnings Call Highlights
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates
Krystal Biotech Analyst Says Stock Weakness 'Overblown'
Krystal Biotech Shares Fall 3.7% Despite Q3 Earnings Beat and 30% Revenue Growth
Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
Krystal Biotech Q3 2026 Earnings Call Transcript
Krystal Biotech Q3 EPS $2.05 Beats $1.77 Estimate, Sales $127.341M Beat $126.079M Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.